CM 4620

Drug Profile

CM 4620

Alternative Names: CM-4620

Latest Information Update: 25 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CalciMedica
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Immunosuppressants; ORAI1 protein inhibitors; STIM1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pancreatitis

Most Recent Events

  • 24 May 2017 CM 4620 receives Fast Track designation for Pancreatitis [Parenteral] in USA
  • 06 Jan 2017 Phase-I clinical trials in Pancreatitis (In volunteers) in USA (Parenteral)
  • 14 Nov 2016 CalciMedica plans phase II trial of CM 4620 for Pancreatitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top